Core Viewpoint - Vincerx Pharma, Inc. is urging stockholders to vote for the Dissolution Proposal, which could lead to potential distributions of $0.04 to $0.08 per share if approved, while delays could reduce or eliminate these distributions [1][2][3]. Group 1: Dissolution Proposal - The Special Meeting to consider the Dissolution Proposal has been adjourned to July 16, 2025, and will be held via live audio webcast [1]. - Vincerx estimates that, upon approval of the Dissolution Proposal, stockholders could receive between $0.04 to $0.08 per share of outstanding common stock [2][7]. - The board of directors unanimously recommends that stockholders vote for the Dissolution Proposal, emphasizing that every vote is crucial and delays could increase costs, reducing potential distributions [3][5]. Group 2: Financial Implications - Continued delays in approving the Dissolution Proposal will lead to ongoing operating costs, which may diminish or eliminate funds available for distribution to stockholders [2][7]. - Timely approval of the Dissolution Proposal may allow U.S. stockholders to recognize capital losses for tax purposes if they receive less than their tax basis in their shares [7]. Group 3: Voting Process - Stockholders are encouraged to vote immediately, with instructions provided for voting by phone or internet [4][7].

Core Viewpoint - Vincerx Pharma, Inc. is set to delist its common stock from Nasdaq due to non-compliance with listing rules, with trading suspended and plans for liquidation announced [2][3][4]. Group 1: Delisting and Trading Suspension - Vincerx received a delisting notice from Nasdaq on April 14, 2025, due to its common stock closing bid price being below the minimum requirement of $1.00 per share for 30 consecutive business days [2]. - Trading of Vincerx's common stock will be suspended at the opening of business on April 23, 2025, and the company intends to file a Form 25 Notification of Delisting with the SEC around April 28, 2025 [1][2]. - An inadvertent suspension of trading occurred on April 16, 2025, but trading will resume on April 21, 2025, until April 22, 2025 [4]. Group 2: Company Actions and Future Plans - The board of directors has decided to dissolve, liquidate, and wind up the company's affairs, distributing any remaining assets to stockholders after settling debts [3]. - Vincerx does not plan to appeal Nasdaq's determination and will not seek to list its common stock on another exchange [3]. - Following the effectiveness of Form 25, Vincerx will file a Form 15 to deregister with the SEC [4]. Group 3: Company Background - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, with a research facility in Monheim, Germany [5].

Core Viewpoint - Vincerx Pharma, Inc. has terminated its non-binding Letter of Intent with Global Digital Holdings Inc. for a potential merger and is now focusing on winding down operations and exploring asset monetization opportunities [1]. Company Actions - The company's board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities [1]. - The Acting CEO expressed gratitude to all stakeholders for their support, highlighting that despite adverse market conditions, patients benefited from therapies during Phase 1 trials [2]. Market Context - The company faced unprecedented adverse market dynamics that hindered the continuation of its development programs [2].

Core Viewpoint - Vincerx Pharma, Inc. has entered into a non-binding letter of intent with Global Digital Holdings Inc. (QumulusAI) for a business combination that would make QumulusAI a publicly traded company through a reverse triangular merger [1][2]. Company Overview - QumulusAI is a high-performance computing infrastructure company focused on artificial intelligence, founded in 2019, with a power portfolio of 108 MW and over 550 GPUs deployed [7]. - Vincerx Pharma's pipeline includes several drug candidates, such as VIP943, VIP236, and enitociclib, which have completed Phase 1 studies [9]. Transaction Details - The proposed merger would result in QumulusAI stockholders owning approximately 95% of the combined company, while Vincerx stockholders would own about 5% [2]. - The transaction values QumulusAI at approximately $285 million and Vincerx at about $15 million, assuming zero cash at closing [2]. - QumulusAI may invest up to $1.5 million in Vincerx's equity prior to closing [2]. Management and Governance - Post-merger, the board of directors of the combined company will consist of seven members, all designated by QumulusAI [3]. - QumulusAI will also determine the senior management composition of the combined entity [3]. Next Steps - The parties plan to negotiate a definitive business combination agreement, with a 30-day exclusivity period for negotiations [4]. - Conditions for the agreement include satisfactory due diligence and approvals from both boards of directors [4]. Strategic Rationale - The merger is expected to create value by entering the rapidly growing AI space, with QumulusAI positioned to disrupt the data center market through its energy-efficient infrastructure [5]. - The transaction will provide access to public capital markets, aiding in the expansion of QumulusAI's data center infrastructure [6].